bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (the Company; bluebird) today announced updates to be presented at the 42nd Annual J.P. Morgan Healthcare conference including commercial launch progress, 2024 program milestones and financial outlook. Andrew Obenshain, chief executive officer, is scheduled to present Tuesday, January 9 at 10:30 a.m. PT/1:30 p.m. ET. “In 2023 bluebird cemented our status as a gene therapy leader, securing our third FDA approval in under two y.

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook

bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why bluebird (BLUE) Stock Might be a Great Pick

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30am PT/1:30pm ET. To access the live webcast of bluebird bio's presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.co.

bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Investors may be tempted to go bottom-fishing after BlueBird Bio's share price drawdown. However, competition from two rivals and a large stock offering should make investors think twice.

Should You Invest in Bluebird Bio Right Now?

Bluebird Bio has proven its innovative capabilities. However, the company likely won't turn a profit soon.

1 Green Flag and 1 Red Flag for Bluebird Bio Stock

CRISPR Therapeutics

By and large, biotech businesses tend to carry significant risks for investors. They're usually at risk of running out of money or their medicines not working.

3 Money-Saving Tricks for Investing in Biotech Stocks in 2024

bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.

bluebird (BLUE) Stock Down on Raising Additional Capital

The plummeting share price is a potent symbol of the structural problems still facing small and midsize biotechs.

Bluebird Bio Stock Is in Free Fall

Biotech company bluebird bio Inc (NASDAQ:BLUE) has priced its underwritten public offering, making 83,333,333 shares of common stock available at $1.50 per share. The offering, expected to yield $125 million in gross proceeds, provides underwriters a 30-day option to purchase an additional 12,499,999 shares.

bluebird bio shares slide on pricing of $125M offering, FDA hurdles

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 83,333,333 shares of its common stock at a public offering price of $1.50 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 12,499,999 shares of its common stock at the public offering price per share, less underwriting discounts and commission.

bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock to be sold in the offering. The offering, actual size and terms are subject to market conditions, and there can be no assurance as to whether or when the offerin.

bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

Bluebird Bio got one of its gene therapies approved recently. Its stock crashed due to certain contingencies associated with the approval.

Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?

bluebird bio Inc (NASDAQ:BLUE) shares took off on Thursday after the biotechnology company provided positive patient start guidance for the new year and revealed a commercial agreement with a U.S. payer that provides coverage to 100 million patients for its recently Food and Drug Administration (FDA)-approved sickle cell therapy Lyfgenia.

bluebird bio stock rises on 2024 patient start guidance; commercial agreement for sickle cell therapy

Bluebird bio said on Thursday a large insurer had agreed to cover its newly approved sickle cell disease gene therapy, easing some investor worries about resistance from other payers over the high price of the treatment.

Bluebird signs pact with insurer for sickle cell gene therapy

DISH Network

Nikola

Novocure

Plug Power

SolarEdge Technologies

SunPower

Wall Street loves a good comeback story. It's why analysts often put elevated price targets on severely beaten-down stocks.

7 Nasdaq Stocks Down 59% Set to Soar at Least 141%

Vertex Pharmaceuticals

The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.

BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies

bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.

bluebird (BLUE) Down Despite FDA Nod to Gene Therapy for SCD

bluebird bio Inc (NASDAQ:BLUE) may have secured FDA approval for its sickle cell disease cell therapy, Lyfgenia, but market reactions have been mixed. Despite the FDA greenlight, BLUE shares experienced a sell-off, driven by concerns over pricing and label dynamics.

bluebird bio faces challenges despite sickle cell therapy approval

SOMERVILLE, Mass.--(BUSINESS WIRE)--Updated data from bluebird bio inc.'s (NASDAQ: BLUE) gene therapy program in transfusion-dependent (TDT) beta-thalassemia were presented today at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. Updated follow-up data showed sustained treatment effect, reduced iron management burden and improved quality of life measures in patients with beta-thalassemia who require regular red blood cell transfusions following treatment with beti.

Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or “bluebird”) today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease through five years of follow-up (median 35.5 months, range 0.3-61 months). Data were highlighted in a press briefing at the 65th American Society of Hematology.

Long-term Follow-up Data From bluebird's Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “bluebird”) today announced the details of its U.S. commercial infrastructure to support timely, equitable access to LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel), an FDA-approved gene therapy for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs). The LYFGENIA launch builds on bluebird's demonstrated success delive.

bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio Announces FDA Approval of LYFGENIA™ for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events.

bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

The U.S. Food and Drug Administration on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics , as well as from bluebird bio.

US approves two gene therapies for sickle cell disease

Bluebird Bio Inc (NASDAQ:BLUE) stock is enjoying a boost today, after an upgrade from Morgan Stanley to "equal-weight" from "underweight," with a price-target hike to $7.00 from $3.00.

Bluebird Stock Upgraded Ahead of Anticipated FDA Approval

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

News for bluebird bio Stock (BLUE)